This is a provocative set of analyses, drawing from two complementary datasets of an NIMH intramural study and the NIMH CATIE Study. The strength of the association between genetic variations in the KCNH2 gene and therapeutic response to antipsychotics is compelling. It is particularly interesting that the predictive power of genetic profile here is even more so than the drug itself. The consistency with independent and complementary studies is noteworthy. This study provides a glimpse of the potential of personalized medicine to move us beyond "trial and error" pharmacotherapy for schizophrenia.

View all comments by Peter F. Buckley